Dashboard
Manage Tickers

CRL CHARLES RIVER LABORATORIES ...

NYSE criver.com


$ 171.87 $ 1.56 (0.92 %)    

Wednesday, 15-Oct-2025 11:24:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 605.38 $ 1.50 (0.25 %)
DIA $ 465.46 $ 0.82 (0.18 %)
SPY $ 668.03 $ 1.26 (0.19 %)
TLT $ 91.18 $ 0.22 (0.24 %)
GLD $ 386.63 $ 0.64 (0.17 %)
$ 170.13
$ 171.31
$ 171.70 x 1
$ 172.05 x 100
$ 171.31 - $ 172.64
$ 91.86 - $ 230.02
580,708
na
8.37B
$ 1.16
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-28-2025 10-Q
2 05-07-2025 03-29-2025 10-Q
3 02-19-2025 12-28-2024 10-K
4 11-06-2024 09-28-2024 10-Q
5 08-07-2024 06-29-2024 10-Q
6 05-09-2024 03-30-2024 10-Q
7 02-14-2024 12-30-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-09-2023 07-01-2023 10-Q
10 05-11-2023 04-01-2023 10-Q
11 02-22-2023 12-31-2022 10-K
12 11-02-2022 09-24-2022 10-Q
13 08-03-2022 06-25-2022 10-Q
14 05-04-2022 03-26-2022 10-Q
15 02-16-2022 12-25-2021 10-K
16 11-03-2021 09-25-2021 10-Q
17 08-04-2021 06-26-2021 10-Q
18 05-04-2021 03-27-2021 10-Q
19 02-17-2021 12-26-2020 10-K
20 11-09-2020 09-26-2020 10-Q
21 10-29-2020 09-26-2020 10-Q
22 08-05-2020 06-27-2020 10-Q
23 05-07-2020 03-28-2020 10-Q
24 02-11-2020 12-28-2019 10-K
25 11-06-2019 09-28-2019 10-Q
26 07-31-2019 06-29-2019 10-Q
27 05-07-2019 03-30-2019 10-Q
28 02-13-2019 12-29-2018 10-K
29 11-07-2018 09-29-2018 10-Q
30 08-08-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 02-13-2018 12-30-2017 10-K
33 11-09-2017 09-30-2017 10-Q
34 08-09-2017 07-01-2017 10-Q
35 05-10-2017 04-01-2017 10-Q
36 02-14-2017 12-31-2016 10-K
37 11-02-2016 09-24-2016 10-Q
38 08-03-2016 06-25-2016 10-Q
39 05-04-2016 03-26-2016 10-Q
40 02-12-2016 12-26-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

earlier-today-charles-river-and-toxys-collaborate-to-offer-reprotracker-assay-for-rapid-developmental-toxicity-testing
Earlier Today: Charles River And Toxys Col...
10/08/2025 14:14:49

Charles River Laboratories International, Inc. (NYSE:CRL) and Toxys today announced a collaboration that offers Charles River&#...

why-charles-river-stock-may-struggle-in-its-final-phase
Why Charles River Stock May Struggle In It...
10/07/2025 11:22:54

Adhishthana.com notes Charles River Stock is nearing its Phase 18, with momentum weakening and long-term outperformance looking...

william-blair-upgrades-charles-river-to-outperform
William Blair Upgrades Charles River to Ou...
10/06/2025 15:27:44

William Blair analyst Matt Larew upgrades Charles River (NYSE:CRL) from Market Perform to Outperform.

evercore-isi-group-maintains-outperform-on-charles-river-raises-price-target-to-200
Evercore ISI Group Maintains Outperform on...
10/03/2025 15:58:24

Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from ...

7-analysts-assess-charles-river-what-you-need-to-know
7 Analysts Assess Charles River: What You ...
10/02/2025 12:02:54

barclays-upgrades-charles-river-to-overweight-raises-price-target-to-195
Barclays Upgrades Charles River to Overwei...
10/02/2025 11:27:27

Barclays analyst Luke Sergott upgrades Charles River (NYSE:CRL) from Equal-Weight to Overweight and raises the price target ...

trump-pfizer-deal-pushes-health-care-stocks-to-best-rally-in-5-years
Trump-Pfizer Deal Pushes Health Care Stock...
10/01/2025 20:22:35

Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tari...

mr-wonderful-kevin-oleary-says-bitcoin-ethereum-enough-to-capture-the-promise-of-crypto-advises-against-irrelevant-tokens
Mr Wonderful Kevin O'Leary Says Bitcoin, E...
09/18/2025 12:31:14

Renowned investor Kevin O’Leary expressed his belief on Wednesday that owning only Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO: ...

charles-river-laboratories-names-michael-knell-interim-cfo-following-resignation-of-flavia-pease-while-comprehensive-cfo-search-commences
Charles River Laboratories Names Michael K...
09/16/2025 11:11:11

breaking-down-charles-river-6-analysts-share-their-views
Breaking Down Charles River: 6 Analysts Sh...
09/09/2025 18:01:33

this-thomson-reuters-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday
This Thomson Reuters Analyst Turns Bullish...
09/09/2025 13:43:30

jefferies-upgrades-charles-river-to-buy-raises-price-target-to-195
Jefferies Upgrades Charles River to Buy, R...
09/09/2025 10:50:12

Jefferies analyst David Windley upgrades Charles River (NYSE:CRL) from Hold to Buy and raises the price target from $142 to ...

is-the-market-bullish-or-bearish-on-charles-river
Is the Market Bullish or Bearish on Charle...
08/15/2025 18:00:32

peter-thiel-backed-bullish-shoots-up-11-after-hours-following-blockbuster-ipo
Peter Thiel-Backed Bullish Shoots Up 11% A...
08/14/2025 03:13:09

Shares of cryptocurrency exchange Bullish soared over 11% in Wednesday's after-hours trading following the company's su...

evercore-isi-group-maintains-outperform-on-charles-river-raises-price-target-to-190
Evercore ISI Group Maintains Outperform on...
08/08/2025 12:27:51

Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from ...

jp-morgan-maintains-neutral-on-charles-river-raises-price-target-to-160
JP Morgan Maintains Neutral on Charles Riv...
08/07/2025 19:09:12

JP Morgan analyst Casey Woodring maintains Charles River (NYSE:CRL) with a Neutral and raises the price target from $145 to ...

barclays-maintains-equal-weight-on-charles-river-raises-price-target-to-165
Barclays Maintains Equal-Weight on Charles...
08/07/2025 13:12:20

Barclays analyst Luke Sergott maintains Charles River (NYSE:CRL) with a Equal-Weight and raises the price target from $155 t...

charles-river-sees-limited-impact-from-nih-cuts-tariffs-drug-pricing
Charles River Sees Limited Impact From NIH...
08/06/2025 16:50:09

Charles River lifts earnings guidance after Q2 beat, citing biotech demand stability, solid DSA performance, and easing regulat...

during-conf-call-charles-river-exec-reportedly-says-effects-of-government-funding-reductions-including-at-nih-have-been-minimal-a-top-priority-in-coming-years-will-be-to-continue-expanding-portfolio-of-nams-through-partnerships-selective-ma-and-internal-development-expects-loss-of-commercial-cdmo-revenue-will-reduce-manufacturing-solutions-growth-rate-by-less-than-500-basis-points-for-2025
During Conf Call, Charles River Exec Repor...
08/06/2025 13:27:18

during-conf-call-charles-river-laboratories-exec-reportedly-says-biotech-environment-stable-but-mixed-with-smaller-biotech-still-being-more-cash-constrained-due-in-part-to-funding-slow-down-mid-sized-biotechs-performing-better-many-able-to-support-own-rd-programs-without-external-funding-have-not-observed-meaningful-impact-on-client-spending-patterns-stemming-from-tariffs-or-drug-pricing-concerns
During Conf Call, Charles River Laboratori...
08/06/2025 13:25:08

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION